Convergent Validity of the Fine Motor, Speech, and Cognitive Domains of the 5-Domain Niemann-Pick Disease Type C Clinical Severity Scale
- PMID: 40525490
- PMCID: PMC12353886
- DOI: 10.1177/08830738251346348
Convergent Validity of the Fine Motor, Speech, and Cognitive Domains of the 5-Domain Niemann-Pick Disease Type C Clinical Severity Scale
Abstract
The 5-Domain Niemann Pick Type C Clinical Severity Scale (5DNPCCSS) is used in clinical practice and trials. Although psychometric data support the clinical meaningfulness of the concepts and the scale's interrater reliability, more information is needed to support its construct validity. Here, we evaluated the convergent validity of the Cognition, Speech, and Fine Motor domains. Data from 121 individuals with Niemann-Pick disease type C were drawn from several studies conducted at 2 US sites. Direct standardized assessments included the Nine-Hole pegboard or Purdue pegboard, a portion of the Clinical Evaluation of Language Fundamentals, and the age-appropriate Wechsler IQ test or the Mullen Scales of Early Learning. The 5DNPCCSS domains were significantly related in the expected directions to their respective direct assessments, supporting their construct validity. In combination with previous evidence presented for the Ambulation and Swallow domains, these results support the fitness of purpose of the (5DNPCCSS for clinical studies in Niemann-Pick disease type C. ClinicalTrials.gov: NCT00344331, NCT01747135, NCT02534844.
Keywords: NPCCSS; Niemann-Pick type C; clinical outcome assessment; validity.
Conflict of interest statement
Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Drs Farmer, Joseph, Giserman-Kiss, and Thurm declare no conflicts of interest. Dr Berry-Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, Avexis, Biogen, BioMarin, Cydan, Engrail, Erydel, Fulcrum, GeneTx, GW, Healx, Ionis, Jaguar, Kisbee, Lumos, Marinus, Mazhi, Moment Biosciences, Neuren, Neurogene, Neurotrope, Novartis, Orphazyme/Kempharm/Zevra, Ovid, PTC Therapeutics, Retrophin, Roche, Seaside Therapeutics, Taysha, Tetra, Ultragenyx, Yamo, Zynerba, and Vtesse/Sucampo/Mallinckrodt Pharmaceuticals, to consult on trial design or run clinical or lab validation trials in genetic neurodevelopmental or neurodegenerative disorders, all of which is directed to Rush University Medical Center (RUMC) in support of rare disease programs; Dr Berry-Kravis receives no personal funds and RUMC has no relevant financial interest in any of the commercial entities listed. Dr Porter's research group has received support as part of a Cooperative Research and Development Agreement between NICHD, NIH, and Vtesse/Sucampo/Mallinckrodt/Mandos to facilitate the development of 2-hydroxypropyl-β-cyclodextrin for the treatment of individuals with Niemann-Pick disease type C.
Figures
References
-
- Runz H, Dolle D, Schlitter AM, Zschocke J. NPC-db, a Niemann-Pick type C disease gene variation database. Human mutation. 2008;29(3):345–350. - PubMed
-
- Imrie J, Dasgupta S, Besley G, et al. The natural history of Niemann–Pick disease type C in the UK. Journal of inherited metabolic disease. 2007;30:51–59. - PubMed
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
